p53 acts in a complex tumor suppressor network that mediates cellular responses to stress. Thus, p53 is? activated in response to diverse cellular insults, including mitogenic oncogenes, hypoxia, oxidative stress,? and DNA damage. Once activated, p53 can trigger a variety of anti-proliferative programs, including? apoptosis and cellular senescence, by targeting multiple components of each program's effector? machineries. Since many of the chemotherapeutic agents currently used to treat cancer directly or indirectly? damage DNA, they often rely on the integrity of the p53 pathway to elicit their anti-tumor effects. As a? consequence, drug resistance can arise as a byproduct of tumor evolution. This project is interested in how? p53 modulates the action of conventional and targeted drugs, and the implications of disrupting the p53? network at different points from tumor evolution to drug resistance. To study these processes, we use the? E-mu-myc transgenic model of B-cell lymphoma as a tractable yet physiological test system. Over the last? funding period, we developed methods to rapidly produce lymphomas with complex genotypes, and then? study the impact of these lesions on tumor cell responses to therapy using approaches that parallel clinical? trials. Using this system, we identified a number of biological (apoptosis, senescence, translational control)? and genetic (p53, ARF, INK4a/ARF, Bcl-2, Akt, elF4E) determinants of drug action. In the current proposal,? we will continue to study components of the p53 network that influence apoptosis and senescence for their? impact on chemosensitivity, and will examine how survival signaling through the PI3kinase/Akt network? affects p53 action to promote chemoresistance. However, we also will initiate efforts to explore the utility of? the E-mu-myc system to study new drugs, in particular, by testing strategies to reverse chemoresistance in? vivo. Furthermore, we will exploit the unique features of the E-mu-myc model to conduct high throughput? screens to identify new genes that influence treatment responses in vivo. We expect that our results will? produce a better understanding of the p53 and Akt networks and how they influence drug sensitivity and? resistance in vivo. By understanding mechanisms of drug resistance and testing strategies to circumvent it,? we may identify new therapeutic targets or treatment strategies that can be extended to clinical trials.
| Rokudai, Susumu; Li, Yingchun; Otaka, Yukihiro et al. (2018) STXBP4 regulates APC/C-mediated p63 turnover and drives squamous cell carcinogenesis. Proc Natl Acad Sci U S A 115:E4806-E4814 |
| Rastogi, Chaitanya; Rube, H Tomas; Kribelbauer, Judith F et al. (2018) Accurate and sensitive quantification of protein-DNA binding affinity. Proc Natl Acad Sci U S A 115:E3692-E3701 |
| Baugh, Evan H; Ke, Hua; Levine, Arnold J et al. (2018) Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ 25:154-160 |
| Agmon, Eran; Solon, Jérôme; Bassereau, Patricia et al. (2018) Modeling the effects of lipid peroxidation during ferroptosis on membrane properties. Sci Rep 8:5155 |
| Yozwiak, Carrie E; Hirschhorn, Tal; Stockwell, Brent R (2018) Toward a Microparticle-Based System for Pooled Assays of Small Molecules in Cellular Contexts. ACS Chem Biol 13:761-771 |
| Hirschhorn, Tal; Stockwell, Brent R (2018) The development of the concept of ferroptosis. Free Radic Biol Med : |
| Liu, Hengrui; Schreiber, Stuart L; Stockwell, Brent R (2018) Targeting Dependency on the GPX4 Lipid Peroxide Repair Pathway for Cancer Therapy. Biochemistry 57:2059-2060 |
| Conrad, Marcus; Kagan, Valerian E; Bayir, Hülya et al. (2018) Regulation of lipid peroxidation and ferroptosis in diverse species. Genes Dev 32:602-619 |
| Zhang, Yan; Larraufie, Marie-Hélène; Musavi, Leila et al. (2018) Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele. Biochemistry 57:1380-1389 |
| Shimada, Kenichi; Reznik, Eduard; Stokes, Michael E et al. (2018) Copper-Binding Small Molecule Induces Oxidative Stress and Cell-Cycle Arrest in Glioblastoma-Patient-Derived Cells. Cell Chem Biol 25:585-594.e7 |
Showing the most recent 10 out of 159 publications
